Loss-of-function mutations protective against human disease provide in vivo validation of therapeutic targets 1-3 , but none have yet been described for type 2 diabetes (T2D). Through sequencing or genotyping of ~150,000 individuals across 5 ancestry groups, we identified 12 rare protein-truncating variants in SLC30A8, which encodes an islet zinc transporter (ZnT8) 4 and harbors a common variant (p.Trp325Arg) associated with T2D risk and glucose and proinsulin levels 5-7 . Collectively, carriers of protein-truncating variants had 65% reduced T2D risk (P = 1.7 × 10 −6 ), and non-diabetic Icelandic carriers of a frameshift variant (p.Lys34Serfs*50) demonstrated reduced glucose levels (−0.17 s.d., P = 4.6 × 10 −4 ). The two most common proteintruncating variants (p.Arg138* and p.Lys34Serfs*50) individually associate with T2D protection and encode unstable ZnT8 proteins. Previous functional study of SLC30A8 suggested that reduced zinc transport increases T2D risk 8,9 , and phenotypic heterogeneity was observed in mouse Slc30a8 knockouts 10-15 . In contrast, loss-of-function mutations in humans provide strong evidence that SLC30A8 haploinsufficiency protects against T2D, suggesting ZnT8 inhibition as a therapeutic strategy in T2D prevention.
pathological pathways. Translation of these loci into novel therapeutic targets 16 requires the identification of causal mutations and genes, as well as information on the directional relationship between protein activity and disease risk 17 . Toward this end, loss-of-function mutations that protect against disease (without adverse phenotypes) are among the most useful findings from human genetics, suggesting targets that, upon inhibition, might prevent disease in the general population.
To identify loss-of-function variants protective against T2D, in 2009, a collaboration of Pfizer, Inc., Massachusetts General Hospital, the Broad Institute and Lund University sequenced the exons of 115 genes near T2D association signals identified by GWAS ( Supplementary Fig. 1 and Supplementary Tables 1 and 2) in 758 individuals from Finland or Sweden (modeling previous studies 18 ). To increase power, we selected individuals at the extremes of T2D risk, including 352 young and lean T2D cases and 406 elderly and obese euglycemic controls 19 (Supplementary Table 3 ). In total, we identified 1,768 nonsynonymous variants (1,683 single-nucleotide variants (SNVs) and 85 indels), 1,474 (83%) with minor allele frequency (MAF) of <1% and 1,108 (63%) observed in only one individual. We found no evidence of association with T2D when testing individual variants or a burden of rare variants within genes ( Supplementary Fig. 2 ). Genotyping of 71 select SNVs (showing nominally significant association (P < 0.05) or predicted to affect Loss-of-function mutations in SLC30A8 protect against type 2 diabetes l e t t e r s protein structure) in up to 13,884 additional individuals (6,388 cases and 7,496 controls) also yielded results consistent with the null distribution of no association with T2D ( Supplementary Fig. 3 ).
Among these SNVs, we noted a nonsense variant (c.412C>T, p.Arg138*) in SLC30A8 (transcript accession NM_173851) that trended toward protection from T2D rather than risk (7 case and 21 control observations, odds ratio (OR) = 0.38, P = 0.05). To propagate this variant into larger sample sizes, we added p.Arg138* to the design of the Illumina Human Exome array (along with six other variants from the original sequencing that were predicted to cause protein truncation). Using this array, we genotyped the 13,884 individuals already genotyped for p.Arg138*, as well as 7,212 additional Finnish or Swedish individuals ( Supplementary  Tables 4 and 5) . In the combined analysis of 10,534 cases and 10,562 controls, the protective association for p.Arg138* remained nominally significant (OR = 0.46, P = 0.01; Supplementary Table 7) , with 16 heterozygotes observed (2 cases and 14 controls). Combining all available genotype data for the variant encoding p.Arg138*, heterozygosity was estimated to yield a 53% reduction in T2D risk (P = 0.0067, N = 48,115).
SLC30A8 encodes an islet zinc transporter ZnT8 (NP_776250; ref. 20) , which is necessary for zinc flux into β cell insulin-secretory granules 4 and subsequent insulin crystallization 10, 12 . Upon cosecretion with insulin, zinc also fulfills autocrine and paracrine signaling roles 21 . A previously identified common missense variant in SLC30A8 (rs13266634; c.973T>A, p.Trp325Arg) associates with T2D risk 7, 22 and glucose 5 and proinsulin 6 levels with significance far exceeding genome-wide thresholds (P < 5 × 10 -8 ).
Cellular characterization has suggested that the risk-increasing allele encoding p.Trp325Arg reduces ZnT8 zinc transport activity 8, 9 .
In Slc30a8 knockout mice, observations range from no effect on insulin secretion or glucose homeostasis to modest hyperglycemia on a high-fat diet, with the phenotype varying with sex and genetic background [8] [9] [10] [11] [12] [13] [14] [15] . Furthermore, data obtained from a recent β cellspecific Slc30a8 knockout mouse model suggest a multi-organ effect on the phenotype, with circulating zinc also influencing hepatic insulin clearance in these mice 21 . Thus, the directional relationship between perturbed ZnT8 function and whole-organism phenotype is uncertain, despite much genetic and biological data.
Because the observed protective association between p.Arg138* and T2D risk was statistically modest, we sought additional evidence. Unfortunately, the near absence of the p.Arg138* variant outside of western Finland limited our ability to further characterize its effect in other populations ( Supplementary Figs. 4 and 5) . We thus sought to identify a wider spectrum of protein-truncating variants in SLC30A8 by investigating the catalog of 35 million variants collected by deCODE Genetics through whole-genome sequencing 23 . The variant encoding p.Arg138* was not observed in this data set. However, an independent protein-truncating variant was observed at a frequency of 0.17%-a deletion (c.100_106delAAAGATC, p.Lys34Serfs*50; Supplementary Figs. 6 and 7) predicted to cause a frameshift and loss of all six transmembrane domains encoded by the islet-specific transcript (NM_173851) of SLC30A8 (ref. 4 l e t t e r s between SLC30A8 protein-truncating variants and reduced T2D risk (combined OR = 0.32, P = 2.4 × 10 −4 ). Both rare SLC30A8 variants are bioinformatically predicted to cause ZnT8 truncation and, consequently, to affect activity. To test this prediction, we assessed overexpressed V5-tagged ZnT8 variants (Trp325, Arg325, *138 (as well as Arg138*) and Ser34fs*50) in HeLa cells 20 (Fig. 1a) . Despite similar RNA transcript levels for all variants ( Supplementary Fig. 8 ), only Trp325 and Arg325 ZnT8 proteins were easily detectable in cells 8 , with Arg138*, *138 and Ser34fs*50 ZnT8 present at low to undetectable levels (Fig. 1b,c) . Similar results were obtained using antibodies against the native protein or the V5 tag in protein blot analysis (Fig. 1b) and immunofluorescence ( Fig. 1c) and in HeLa as well as in Ins1e rat insulinoma cells (Fig. 1d) . Coexpression of *138 or Ser34fs*50 ZnT8 with Trp325 ZnT8 did not decrease expression of the full-length allele or rescue expression of either truncating variant (Supplementary Fig. 9 ).
We hypothesized that decreased expression of these two mutants might be due to protein instability and/or enhanced degradation. After treatment of cells with chloroquine or MG132 (lysosomal and proteasomal inhibitors, respectively 24 ), higher *138 and Ser34fs*50 ZnT8 expression was detected via immunofluorescence (but remained undetectable via protein blot analysis; Fig. 1e and Supplementary Fig. 10 ). These results are consistent with but do not prove instability and subsequent degradation of these truncated proteins 25 . In additional experiments (data not shown), we observed zinc transport in cells expressing Arg325 and Trp325 ZnT8 but not in cells expressing *138 or Ser34fs*50 ZnT8 (an expected result given the low levels of mutant protein). Further experiments are needed to assess the in vivo impact of these variants, including their susceptibility to nonsense-mediated decay and potential dominant-negative effects on protein oligomerization.
These genetic and functional data suggest that SLC30A8 haploinsufficiency reduces T2D risk. However, confidence in this conclusion would be further increased through the observation of multiple additional putative loss-of-function variants demonstrating protective effects. As part of the Genetics of Type 2 Diabetes (Go-T2D) and Type 2 Diabetes Genetic Exploration by Next-Generation Sequencing in Multi-Ethnic Samples (T2D-GENES) consortia, we sequenced SLC30A8 exons in 12,294 individuals spanning multiple ancestry groups (Supplementary Table 10 ). Nine additional protein-truncating variants were identified-2 frameshift indels and 2 nonsense, 4 splice-site and 1 initiator codon SNV-in 23 heterozygous individuals of African-American, East Asian and South Asian ancestry (Supplementary Data Set 1) . The variant encoding p.Arg138* was seen in three additional carriers (one case and two controls); the variant encoding p.Lys34Serfs*50 was not observed.
In aggregate, carriers of these additional variants exhibited 60% reduced T2D risk (4 observations of the variants in cases versus 18 observations in controls; OR = 0.38, P = 0.0025), with similar effects and statistical significance observed upon analysis of only carriers of frameshift or nonsense variants (2 observations of variants in cases versus 13 observations in controls; OR = 0.37, P = 0.0027). Combining all data from sequencing and genotyping in 149,134 subjects, heterozygosity for any of the 12 protein-truncating variants was associated with 65% reduced T2D risk (OR = 0.34, P = 1.7 × 10 −6 ), which represents a statistically significant association even after correction for the ~20,000 genes in the human genome ( Table 1) . Through sequencing and genotyping of ~150,000 individuals across 5 ancestry groups, a spectrum of 12 rare predicted protein-truncating variants was identified in SLC30A8. Shown for each variant are ancestry group, cohort, number of genotyped cases and controls (N), number of cases and controls observed to carry the variant, and observed allele frequencies in cases and controls. ORs and P values were computed separately for three groups of variants: p.Arg138*, p.Lys34Serfs*50 and the remaining variants. For p.Arg138* and p.Lys34Serfs*50, for which more than ten carriers were observed, statistics were computed separately for each cohort (Online Methods and supplementary Note) and then combined via a fixed-effects meta-analysis. For the remaining variants, an association score was computed by comparing the aggregate frequencies of variant carriers in cases and controls. These three statistics were combined via a random-effects meta-analysis to produce combined estimates of risk and statistical significance (bottom row). Variant counts and frequencies were computed on the basis of all studied individuals, whereas ORs and P values were computed with correction for sample structure (population stratification and genetic relatedness; supplementary Note); thus, displayed ORs differ from those computed solely from frequency estimates. CI, confidence interval.
l e t t e r s
We investigated potential confounding factors for the observed protective association. First, we assessed whether the haplotypic background encoding the p.Trp325Arg variant might influence results. Whereas the variants encoding p.Lys34Serfs*50 and p.Met50Ile were observed on the protective common variant haplotype, the remaining variants (including the one encoding p.Arg138*) were observed on the risk-associated common variant haplotype. Thus, independent protective protein-truncating variants were observed on opposite haplotypic backgrounds encoding p.Trp325Arg. Second, we tested for a survivor effect, where carriers of rare variants with diabetes would die at a younger age than non-carriers. However, (i) carrier ages did not differ significantly from non-carrier ages for either p.Arg138* (69.6 ± 8.4 years versus 65.5 ± 11.0 years for cases (P > 0.1), 46.4 ± 15.7 years versus 50.3 ± 15.5 years for controls (P > 0.1)) or p.Lys34Serfs*50 (70.5 ± 4.5 years versus 65.6 ± 13.8 years for cases (P > 0.1), 48.5 ± 20.1 years versus 50.0 ± 23.2 years for controls (P > 0.1)), and (ii) p.Lys34Serfs*50 association attained equivalent significance even when the analysis was restricted to age-matched controls. Finally, although we employed well-established methods using linear mixed models or principal components to control for population structure 26 , we acknowledge the noted challenges to address this potential confounder in rare variant association studies 27 . We had insufficient data to control for stratification via a family-based transmission disequilibrium test (pedigree information was only available for Icelanders, with three carrier parents all transmitting the risk-associated allele to affected children). However, the consistent association of multiple independent protein-truncating variants across multiple cohorts and ancestry groups argues against population stratification being responsible for protective association.
These data thus provide compelling evidence that mutations inactivating one copy of SLC30A8 reduce T2D risk in humans. In addition to T2D risk, the common SLC30A8 variant encoding p.Trp325Arg is associated with proinsulin and fasting plasma glucose levels at genome-wide significance 5, 6 , as well as with 2-h glucose levels after an oral glucose tolerance test (OGTT) at nominal significance (Supplementary Table 11 ) 27 . We asked whether rare protein-truncating SLC30A8 variants also affected T2D-related phenotypes, particularly glycemic traits that might be indicative of altered islet function.
Among the traits analyzed (Supplementary Table 12) , the strongest statistical evidence for association was observed in Icelanders between p.Lys34Serfs*50 and random (non-fasting) glucose levels: non-diabetic carriers of the protective allele had lower glucose levels (β = −0.17 s.d.; N = 182 carriers; P = 4.6 × 10 −4 ), with a consistent effect seen in three Norwegian carriers (β = −0.3 s.d.; P > 0.1). Glucose levels were lower at 1 h in the small number of p.Lys34Serfs*50 carriers characterized by OGTT (β = −0.73 s.d.; N = 4 carriers; P = 0.05). We did not observe a significant difference in fasting glucose or insulin levels, although the directions of effect were consistent with those described above-these levels were lower for fasting glucose (average β = −0.10 s.d.; N = 146 carriers; P > 0.1) and higher for fasting insulin (β = 0.24 s.d.; N = 52 carriers; P = 0.09). The parallel directionality of glucose levels and T2D risk is similar to the pattern observed for p.Trp325Arg, where the T2D-protective allele also associates with lower glucose levels (Supplementary Table 9 ), providing further evidence against a survivor effect or population stratification driving the protective association.
In summary, we identified 12 rare predicted protein-truncating SLC30A8 variants (Fig. 2) . Carriers of these variants had 65% reduced T2D risk at a level of significance adequate to correct for the ~20,000 genes in the human genome (P = 1.7 × 10 −6 ). Non-diabetic Icelandic carriers of p.Lys34Serfs*50 also demonstrated lower glucose levels (β = −0.17 s.d., P = 4.6 × 10 −4 ). Notably, initial sequencing of 115 genes in 758 individuals with extreme T2D phenotypes resulted in only 2 observations of the variant encoding p.Arg138*, without significant evidence of association of low-frequency or rare variants, individually or in aggregate, for any of the sequenced genes. Rather, establishing the association of SLC30A8 protein-truncating variants with T2D protection at levels of exome-wide significance (with correction for 20,000 genes) required genotyping of ~150,000 individuals spanning multiple ancestry groups. Detecting similar effects in genes without previous evidence of association may require analysis on a similar or larger scale, for not only T2D but also for other complex traits. npg l e t t e r s
Previous modeling of the relationship between ZnT8 activity and T2D risk centered on p.Trp325Arg, which results in mildly attenuated zinc transport that is concomitant with increased T2D risk 8 , and Slc30a8 knockout mice, where phenotypic heterogeneity is observed 13, 15 . We find a clear and consistent association between putative SLC30A8 loss-of-function variants and T2D risk across multiple ancestry groups, demonstrating convincingly that a 50% reduction in gene dosage protects against T2D in humans. These data reject the model in which loss of ZnT8 function is associated with as little as a 1.2-fold increase in T2D risk (similar to the increase in risk observed for the common p.Trp325Arg variant) at significance of P ≈ 1 × 10 −9 . Phenotypic interrogation of human mutation carriers is needed to determine the physiological mechanism behind this protective association and to establish the effects of SLC30A8 haploinsufficiency in the pancreas and other tissues 21 .
The observed human genetics data present several implications for SLC30A8 function in T2D pathophysiology. The identification of multiple disease-associated protein-altering variants in SLC30A8 unambiguously (albeit unsurprisingly) documents SLC30A8 as the causal gene behind GWAS association signals. The observation that protein-truncating variants protect against T2D defines the directional relationship between ZnT8 activity and T2D risk in humans. The expanded SLC30A8 allelic series offers a more functionally informative catalog of variation compared to the p.Trp325Arg variant alone, enabling future experiments investigating potential mechanisms. Although substantial work is required to understand how reduced ZnT8 activity lowers T2D risk, the current observations motivate experiments to test ZnT8 inhibition in T2D treatment in human populations.
MeThoDS
Methods and any associated references are available in the online version of the paper. 
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